News
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH)
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
IMV Inc. Announces Changes to Its Board of Directors
IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today
Transgene Announces Upcoming Investor Meetings
Regulatory News:
TRANSGENE (Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces that Management will participate in
Sartorius Stedim Biotech SA: René Fáber takes over as Chief Executive Officer of Sartorius Stedim Biotech S.A.; Joachim Kreuzburg remains Chairman of the Board
Uni-Bio Science Group Limited: 2022 Annual Results
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Lonza Publishes Invitation to the 2023 Annual General Meeting and 2022 Annual and Sustainability Reports
EQS-News: Eckert & Ziegler Plans Change of Legal Form to European Stock Corporation (SE)
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
EQS-News: Heidelberg Pharma concludes very successful financial year 2022 and reports on course of business
Evolva publishes agenda for 2023 Annual General Meeting
Agilent Presents 2023 Darlene Solomon Award to Victor Chang Cardiac Research Institute Scientist, Kathryn Wolhuter
Agilent Technologies Inc. (NYSE: A) announced today that the recipient of the 2023 Darlene Solomon Award is Kathryn Wolhuter, Ph.D., a senior postdoctoral researcher studying coronary heart disease
EQS-News: Eckert & Ziegler with Unchanged Dividend Proposal
EQS-News: Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.85 per share
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Poxel Announces Cash Runway Extended Through Q2 2025 Based upon Debt Restructuring Agreement and New Equity-linked Financing Facility
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic
Poxel Reports Financial Results for Full Year 2022 and Provides Corporate Update
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic